Mohamed Ragab has been appointed vice president of corporate development at iTeos Therapeutics SA which is developing immunotherapies for cancer. Dr Ragab was most recently an executive at Bristol-Myers Squibb Co where he was involved in immuno-oncology transactions. Prior to this, he was global head of oncology partnering at Roche, and also held positions at Pfizer Inc, Ortho Biotech Inc and Schering-Plough (now Merck & Co Inc).
Dr Ragab holds a master’s degree in radiation oncology and a bachelor’s degree in medicine and surgery from Cairo University School of Medicine in Egypt.
iTeos Therapeutics announced the appointment on 29 June 2017.
Copyright 2017 Ever